TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib
Dandan Wu, Xuexian O. Yang
Abstract
COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.
Topics & Concepts
Cytokine stormCoronavirus disease 2019 (COVID-19)MedicinePandemic2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseImmune systemImmunologyVirologyInternal medicineInfectious disease (medical specialty)OutbreakCytokine Signaling Pathways and InteractionsSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies